Synthetic antibodies show efficacy against bunyaviruses, study finds
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
List view / Grid view
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
Multidrug nanoparticles for the targeted delivery of drugs could be used to combat inflammation in COVID-19 patients, say researchers.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
The antibody targets a cell receptor in blood vessels and slowed breast and lung cancer growth as well as metastasis in murine models.
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
Researchers investigating telomere dieases such as dyskeratosis congenita have found lead compounds that reverse cellular ageing in mouse models of the condition.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.